Movement Alert|Twist Bioscience Corp Rises 5.45% in Pre-Market Trading, Revenue Guidance Far Exceeds Expectations Boosting Market Confidence

Market Focus08-05

On August 5, Twist Bioscience Corp rose 5.45% in pre-market trading, trading at $104.86/share, with turnover of $962,000.

On the news front, the company previously reported fiscal Q3 results with revenue of $118.4 million, up 23.2% year-over-year and beating the analyst consensus estimate of $114.5 million. More notably, the company raised its full-year revenue guidance to $456 million to $457 million and projected Q4 revenue of $123 million to $124 million, significantly above the FactSet consensus estimate of $117.4 million. While the quarterly EPS loss of $0.56 missed market expectations of a $0.51 loss and marked a reversal from the $0.33 per share profit in the year-ago period, the strong top-line momentum and above-consensus forward guidance continued to bolster investor confidence in the company's business expansion trajectory, driving the pre-market rebound.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment